Page 47 - 《中国药房》2025年18期
P. 47
成、侵袭能力均显著回升,且接近对照组水平。这提示 migration via PI3K/Akt pathway[J]. Oncotarget,2018,9
PI3K/Akt 信号通路可能是 EGCG 增强仑伐替尼抗肝癌 (15):12261-12272.
活性的关键调控靶点。 [13] MEHMOOD S,MAQSOOD M,MAHTAB N,et al. Epi‐
综上所述,EGCG可增加肝癌细胞对仑伐替尼的敏 gallocatechin gallate:phytochemistry,bioavailability,utili‐
感性,其作用机制可能与抑制PI3K/Akt信号通路激活有 zation challenges,and strategies[J]. J Food Biochem,
2022,46(8):e14189.
关。本研究为增强仑伐替尼治疗敏感性提供了实验参
[14] GU J J,QIAO K S,SUN P,et al. Study of EGCG induced
考,对挖掘新的治疗策略、提高肝癌患者的治疗效果具
apoptosis in lung cancer cells by inhibiting PI3K/Akt sig‐
有重要意义。
naling pathway[J]. Eur Rev Med Pharmacol Sci,2018,22
参考文献 (14):4557-4563.
[ 1 ] 赵海潮,高强 . 2022 年度肝癌研究及诊疗新进展[J]. 中 [15] WEI Y C,YANG L,TANG C W,et al. Lenvatinib inhibits
国癌症杂志,2023,33(4):315-326. cholangiocarcinoma progression by targeting the FGF19/
[ 2 ] 张劲丰,安宏亮,苏荣,等. 乙型肝炎病毒耐药性研究进 PI3K/Akt signaling pathway[J]. Apoptosis,2025,30(1/
展[J]. 分子诊断与治疗杂志,2019,11(5):434-440. 2):185-196.
[ 3 ] 熊洪莉,陈君辉,王雪. 心理护理对介入治疗围手术期肝 [16] LIU S M,SUN Z W,CHU P,et al. EGCG protects against
癌患者焦虑抑郁水平影响的临床对照研究[J]. 四川精神 homocysteine-induced human umbilical vein endothelial
卫生,2015,28(3):227-229. cells apoptosis by modulating mitochondrial-dependent
[ 4 ] NAING C,NI H,AUNG H H,et al. Gene therapy for apoptotic signaling and PI3K/Akt/ENOS signaling path‐
people with hepatocellular carcinoma[J]. Cochrane Data‐ ways[J]. Apoptosis,2017,22(5):672-680.
base Syst Rev,2024,6(6):CD013731. [17] DING F,YANG S. Epigallocatechin-3-gallate inhibits pro‐
[ 5 ] 杨欣荣,孙惠川,谢青,等. 仑伐替尼肝癌全病程应用中 liferation and triggers apoptosis in colon cancer via the
国专家指导意见[J]. 中华消化外科杂志,2023,22(2): hedgehog/phosphoinositide 3-kinase pathways[J]. Can J
167-180. Physiol Pharmacol,2021,99(9):910-920.
[ 6 ] WANG L,LIN L,ZHOU W. Efficacy and safety of trans- [18] 李明龙. EGCG逆转索拉菲(非)尼耐药肝癌细胞的相关
arterial chemoembolization combined with lenvatinib and 机制研究[D]. 延吉:延边大学,2016.
PD-1 inhibitor in the treatment of advanced hepatocellular [19] ZHAI J,HAO H,XU Z,et al. The effect of modulation
carcinoma:a meta-analysis[J]. Pharmacol Ther,2024, Piezo2 by IGF-1 on tactile hypersensitivity in BTBR
257:108634. model mice[J]. Life Sci,2025,364:123449.
[ 7 ] CHAN L L,CHAN S L. The evolving role of lenvatinib at [20] 中华人民共和国国家卫生健康委员会医政司. 原发性肝
the new era of first-line hepatocellular carcinoma treat‐ 癌诊疗指南:2024 年版[J]. 中华肝脏病杂志,2024,32
ment[J]. Clin Mol Hepatol,2023,29(4):909-923. (7):581-630.
[ 8 ] LU Y G,SHEN H M,HUANG W J,et al. Genome-scale [21] YANO S,KAWAOKA T,JOHIRA Y,et al. Advanced he‐
CRISPR-Cas9 knockout screening in hepatocellular carci‐ patocellular carcinoma with response to lenvatinib after
noma with lenvatinib resistance[J]. Cell Death Discov, atezolizumab plus bevacizumab[J]. Medicine(Baltimore),
2021,7(1):359. 2021,100(42):e27576.
[ 9 ] TALIB W H,AWAJAN D,ALQUDAH A,et al. Targeting [22] BUTTELL A,QIU W. The action and resistance mecha‐
cancer hallmarks with epigallocatechin gallate(EGCG): nisms of lenvatinib in liver cancer[J]. Mol Carcinog,
mechanistic basis and therapeutic targets[J]. Molecules, 2023,62(12):1918-1934.
2024,29(6):1373. [23] GUAN Y T,WU Q L,LI M M,et al. Epigallocatechin-
[10] ALMATROODI S A,ALMATROUDI A,KHAN A A,et 3-gallate induced HepG2 cells apoptosis through ROS
al. Potential therapeutic targets of epigallocatechin gallate mediated Akt/JNK and p53 signaling pathway[J]. Curr
(EGCG),the most abundant catechin in green tea,and its Cancer Drug Targets,2023,23(6):447-460.
role in the therapy of various types of cancer[J]. Mole- [24] MORADZADEH M,HOSSEINI A,ERFANIAN S,et al.
cules,2020,25(14):3146. Epigallocatechin-3-gallate promotes apoptosis in human
[11] DU B X,LIN P,LIN J. EGCG and ECG induce apoptosis breast cancer T47D cells through down-regulation of
and decrease autophagy via the AMPK/mTOR and PI3K/ PI3K/Akt and telomerase[J]. Pharmacol Rep,2017,69
Akt/mTOR pathway in human melanoma cells[J]. Chin J (5):924-928.
Nat Med,2022,20(4):290-300. (收稿日期:2025-03-26 修回日期:2025-07-29)
[12] LUO K W,LUNG W Y,CHUN-XIE,et al. EGCG inhi- (编辑:张元媛)
bited bladder cancer T24 and 5637 cell proliferation and
中国药房 2025年第36卷第18期 China Pharmacy 2025 Vol. 36 No. 18 · 2261 ·

